US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zenas BioPharma Inc.

11.12

+1.5115.71%

Post-market: 11.330.2100+1.89%19:56 EDT

Volume:198.09K

Turnover:2.12M

Market Cap:465.20M

PE:-1.59

High:11.28

Open:9.76

Low:9.61

Close:9.61

Loading ...

Overview Company News Filings

Zenas Biopharma Appoints Lisa Von Moltke, M.d., as Head of Research and Development and Chief Medical Officer

THOMSON REUTERS

Press Release: Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

Simply Wall St.

Director Makes Bold Move with Major Stock Purchase in Zenas BioPharma!

BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives

Zenas Biopharma- Cash Equivalents, Short-Term Investments as of Dec 31 to Fund Operating Expenses & Capex Requirements Into Q4 2026

THOMSON REUTERS

Zenas Biopharma :Topline Results From Pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (Indigo) Expected Year-End 2025

THOMSON REUTERS

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Zenas BioPharma Initiated at Outperform by Wolfe Research

Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target

MT Newswires Live

Zenas BioPharma initiated with an Outperform at Wolfe Research

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Zenas BioPharma initiated with a Buy at H.C. Wainwright

HC Wainwright Initiates Zenas BioPharma at Buy With $30 Price Target

MT Newswires Live

Zenas BioPharma Initiated at Buy by HC Wainwright & Co.

Zenas Biopharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

Zenas BioPharma Is Maintained at Overweight by Morgan Stanley

Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

Zenas Biopharma Inc : Morgan Stanley Cuts Target Price to $35.00 From $40.00

THOMSON REUTERS

Strategic Shift and Positive Outlook Justify Buy Rating for Zenas BioPharma, Inc.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ZBIO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":11.12,"timestamp":1749240000000,"preClose":9.61,"halted":0,"volume":198092,"hourTrading":{"tag":"盘后","latestPrice":11.33,"preClose":11.12,"latestTime":"19:56 EDT","volume":1266,"amount":14100.82,"timestamp":1749254198045},"delay":0,"floatShares":20950537,"shares":41834182,"eps":-6.997271,"marketStatus":"Market Closed","change":1.51,"latestTime":"06-06 16:00:00 EDT","open":9.76,"high":11.28,"low":9.61,"amount":2115783.806888,"amplitude":0.173777,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.997271,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":9.61,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"dividendRate":0.00009,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":9.81,"preClose":9.61,"latestTime":"08:50 EDT","volume":40,"amount":392.40000000000003,"timestamp":1749214214138},"postHourTrading":{"tag":"盘后","latestPrice":11.33,"preClose":11.12,"latestTime":"19:56 EDT","volume":1266,"amount":14100.82,"timestamp":1749254198045},"volumeRatio":1.1840044752562344},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":20950537,"roa":"-56.70%","roe":"-115.47%","lyrEps":-11.893967,"volumeRatio":1.1840044752562344,"shares":41834182,"dividePrice":0.001,"high":11.28,"amplitude":0.173777,"preClose":9.61,"low":9.61,"week52Low":5.83,"pbRate":"1.64","psRate":"31.01","week52High":26.2508,"institutionHeld":0,"latestPrice":11.12,"eps":-6.997271,"divideRate":0.00009,"volume":198092,"delay":0,"ttmEps":-6.997271,"open":9.76,"prevYearClose":8.19,"prevWeekClose":9.52,"prevMonthClose":9.52,"prevQuarterClose":7.9,"fiveDayClose":9.52,"twentyDayClose":9.29,"sixtyDayClose":8.21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520549984","title":"Zenas Biopharma Appoints Lisa Von Moltke, M.d., as Head of Research and Development and Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520549984","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520549984?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:05","pubTimestamp":1742209500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUA2SXT6X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2520499695","title":"Press Release: Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520499695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520499695?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:05","pubTimestamp":1742209500,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer. --Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies--. Dr. von Moltke most recently served as CMO at Seres Therapeutics with functional oversight of clinical development, sciences and operations, and regulatory and medical affairs. Prior to Seres, Dr. von Moltke served in roles of increasing responsibility at Alkermes, Inc., culminating as Senior Vice President and Head of Clinical Development. Before joining Alkermes, Dr. von Moltke was Vice President, Clinical and Exploratory Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences  and Early Development and later as Head of CEP for Japan and China. Earlier in her career, Dr. von Moltke was Head, Translational","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO","CEP"],"gpt_icon":0},{"id":"2519833894","title":"Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519833894","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519833894?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:27","pubTimestamp":1741865272,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So, the natural question for Zenas BioPharma  shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.Since it has a market capitalisation of US$303m, Zenas BioPharma's US$120m in cash burn equates to about 40% of its market value. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zenas-biopharma-nasdaq-zbio-good-112752658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","IE00BKPKM429.USD","LU2210149790.SGD","MNQmain","QLD","SQQQ","BK4139","IE00B64PRP62.GBP","NQmain","LU2210150020.SGD","IE00BGHQF748.EUR","ZBIO","BK4585",".IXIC","NDAQ","USAW.SI","USJW.SI","QID","BK4588","BK4112","NVIW.SI","PSQ","IE00B3QW5Z07.USD","TQQQ","LU2095319765.USD"],"gpt_icon":1},{"id":"2510993343","title":"Director Makes Bold Move with Major Stock Purchase in Zenas BioPharma!","url":"https://stock-news.laohu8.com/highlight/detail?id=2510993343","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510993343?lang=en_us&edition=fundamental","pubTime":"2025-02-12 10:02","pubTimestamp":1739325772,"startTime":"0","endTime":"0","summary":"New insider activity at Zenas BioPharma, Inc. ( ($ZBIO) ) has taken place on February 12, 2025. Director Ting Xiao has made a significant investmen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-zenas-biopharma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-zenas-biopharma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2509004414","title":"BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2509004414","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509004414?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:36","pubTimestamp":1738759009,"startTime":"0","endTime":"0","summary":"BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives Feb 5 (Reuters) - Zenas Biopharma Inc ZBIO.O:ZENAS BIOPHARMA : TOPLINE RESULTS FROM PHASE 2 TRIAL IN RELAPSING MUL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW195:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2509840786","title":"Zenas Biopharma- Cash Equivalents, Short-Term Investments as of Dec 31 to Fund Operating Expenses & Capex Requirements Into Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2509840786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509840786?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:09","pubTimestamp":1738757393,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW0Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2509407893","title":"Zenas Biopharma :Topline Results From Pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (Indigo) Expected Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509407893?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:08","pubTimestamp":1738757333,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW195:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2509407986","title":"Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407986","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509407986?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:05","pubTimestamp":1738757100,"startTime":"0","endTime":"0","summary":"- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021061/0/en/Zenas-BioPharma-Announces-Key-2024-Accomplishments-and-2025-Business-Objectives-to-Support-the-Global-Development-and-Commercialization-of-Therapies-for-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","ZBIO","BK4139","SLE"],"gpt_icon":0},{"id":"2508026459","title":"Zenas BioPharma Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2508026459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508026459?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:26","pubTimestamp":1738675560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2025 08:26 ET (13:26 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2508455597","title":"Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2508455597","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508455597?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:44","pubTimestamp":1738673073,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) has an average rating of Buy and mean price target of $33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO"],"gpt_icon":0},{"id":"2508175688","title":"Zenas BioPharma initiated with an Outperform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175688?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:35","pubTimestamp":1738618547,"startTime":"0","endTime":"0","summary":"Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating. Published first on TheFly – the ultimate source for real-tim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-initiated-with-an-outperform-at-wolfe-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-initiated-with-an-outperform-at-wolfe-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2506513319","title":"Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2506513319","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506513319?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan.  28, 2025  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016303/0/en/Zenas-BioPharma-to-Present-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4011","BK4139","SMID","ZBIO"],"gpt_icon":0},{"id":"2492395883","title":"Zenas BioPharma initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2492395883","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492395883?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:25","pubTimestamp":1734434721,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Zenas BioPharma  with a Buy rating and $30 price target The company’s lead autoimmune therapy, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc gamma receptor IIb, FcgammaRIIb, broadly present on B cell lineage, the analyst tells investors in a research note. The firm believes obexelimab represents an autoimmune franchise molecule with the potential for B cell therapeutic differentiation.Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley. Zenas BioPharma completed targeted enrollment of Phase 3 INDIGO trial. Zenas BioPharma initiated with a Buy at Rodman & Renshaw","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CelDdPDqWVkcG2SiBC__kg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CelDdPDqWVkcG2SiBC__kg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/zenas-biopharma-initiated-buy-h-112521565.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zenas-biopharma-initiated-buy-h-112521565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","LU0098860793.USD","LU1363072403.SGD","LU0225283273.USD","BK4516","LU1720051017.SGD","LU2111349929.HKD","LU0971096721.USD","LU2089283258.USD","BK4127","BK4581","BK4585","LU1989772923.USD","LU1989772840.SGD","LU0158827948.USD","LU2089284900.SGD","BK4139","LU1668664300.SGD","LU0106831901.USD","LU1074936037.SGD","LU2023251221.USD","LU2271345857.HKD","BK4534","LU0314104364.USD","LU0320765646.SGD","IE00BKVL7J92.USD","ZBIO","LU0267386448.USD","LU0006306889.USD","LU1548497426.USD","BK4588","LU1162221912.USD","LU2357305700.SGD","LU2028103732.USD","LU0106261372.USD","IE00BZ1G4Q59.USD","LU0158827781.USD","LU1720051108.HKD"],"gpt_icon":0},{"id":"2491469843","title":"HC Wainwright Initiates Zenas BioPharma at Buy With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2491469843","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491469843?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:48","pubTimestamp":1734353309,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) has an average rating of buy and mean price target of $34.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO"],"gpt_icon":0},{"id":"2491569865","title":"Zenas BioPharma Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2491569865","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491569865?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:39","pubTimestamp":1734352740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2024 07:39 ET (12:39 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2491669791","title":"Zenas Biopharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2491669791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491669791?lang=en_us&edition=fundamental","pubTime":"2024-12-16 19:19","pubTimestamp":1734347942,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nAZN2UG6OQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2490877852","title":"Zenas BioPharma Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2490877852","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490877852?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:33","pubTimestamp":1733923980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2024 08:33 ET (13:33 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2490856417","title":"Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2490856417","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490856417?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:35","pubTimestamp":1733920537,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Zenas BioPharma (ZBIO) to $35 from $40 and keeps an Overweight rating on the shares. The firm upd...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-lowered-to-35-from-40-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-lowered-to-35-from-40-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2490832168","title":"Zenas Biopharma Inc : Morgan Stanley  Cuts Target Price to $35.00 From $40.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2490832168","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490832168?lang=en_us&edition=fundamental","pubTime":"2024-12-11 18:51","pubTimestamp":1733914273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nAZN2T1VCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2490832787","title":"Strategic Shift and Positive Outlook Justify Buy Rating for Zenas BioPharma, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2490832787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490832787?lang=en_us&edition=fundamental","pubTime":"2024-12-11 18:47","pubTimestamp":1733914059,"startTime":"0","endTime":"0","summary":"In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Zenas BioPharma, Inc. (ZBIO – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strategic-shift-and-positive-outlook-justify-buy-rating-for-zenas-biopharma-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strategic-shift-and-positive-outlook-justify-buy-rating-for-zenas-biopharma-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"ZBIO","fiscalQuarterEnding":"2025/03","expectedEps":-1.15,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2024/09","expectedEps":13,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-5.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.7143,"buy":0.2857,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.7143,"analysts":7,"updateTime":1742529600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2025-06-06","current":-2.470042,"percent":0.675824,"low":-19.592941,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"high":-1.802568,"avg":-5.501129,"sd":5.106403,"marketCap":402026489},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489}],"updateTime":1749409867121}}}